BioSpace News Archive

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights.

OpGen, Inc. announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.

Apogee Therapeutics, Inc. today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG777, its lead product candidate being developed as a frontline treatment for moderate-to-severe AD and other inflammatory diseases.

Palatin Technologies, Inc. today announced that it has entered a strategic partnership with UpScriptHealth, a leading direct-to-consumer telemedicine company providing telemedicine services to pharmaceutical and medical technology companies.

Ligandal Inc. announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer.

MBX Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for MBX 1416, the company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for the treatment of post-bariatric hypoglycemia (PBH).

Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000th peer-reviewed article citing use of the company’s technology, the largest publication volume in the industry.

Longeveron Inc. announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023.

Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for the accurate & precise quantification of hemoglobins F and A2, and the detection of >200 hemoglobin variants.

IceCure Medical Ltd. today announced that it will release its financial and operational results as of and for the six months ended June 30, 2023 with a press release prior to the market open on Monday, August 14, 2023 and will host a conference call at 10:00 a.m. EDT that day to discuss the results and corporate developments.